BBLG Bone Biologics Corporation
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.…
Industry Peers
BiotechnologyKey Statistics
About Bone Biologics (NASDAQ: BBLG)
›
Bone Biologics (NASDAQ: BBLG) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 2 employees.
The shares were at 0.3251 USD on 13 November 2026, down 81.6% over 52 weeks. Its 52-week range is 0.3150 USD to 2.390 USD: the price is 86.4% below the high and 3.2% above the low.
Its market capitalisation is 1.10M USD.
Bone Biologics reports return on equity of -57.8% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 6.09M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.